Kymera Therapeutics, Inc.Kymera Therapeutics, Inc.Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.

No trades
See on Supercharts

Price target

57.760.000.00%
The 17 analysts offering 1 year price forecasts for KYMR have a max estimate of — and a min estimate of —.

Analyst rating

Based on 18 analysts giving stock ratings to KYMR in the past 3 months.

EPS

‪0.00‬
Reported
Estimate
Reported
Estimate
Surprise

Revenue

‪0.00‬
Reported
Estimate
Reported
Estimate
Surprise
Be warned

Frequently Asked Questions


KYMR EPS for the last quarter is −0.82 USD despite the estimation of −0.83 USD. In the next quarter EPS is expected to reach −0.77 USD. Track more of Kymera Therapeutics, Inc. financials and stay on top of what is up with the company.
In the next quarter Kymera Therapeutics, Inc. revenue is expected to reach ‪15.24 M‬ USD. Check out Kymera Therapeutics, Inc. revenue and earnings and make informed decisions.
According to analysts, KYMR price target is 57.76 USD with a max estimate of 90.00 USD and a min estimate of 38.00 USD. Check if this forecast comes true in a year, meanwhile watch Kymera Therapeutics, Inc. stock price chart and keep track of the current situation with KYMR news and stock market news.
We've gathered opinions of 18 analysts rating KYMR stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as strong buy. Note that it's not a trading advice — your own analysis is still required.